Duchenne muscular dystrophy treatment with lentiviral vector containing mini‐dystrophin gene in vivo

Xiaoyu Wang, Yanghui Zhu, Taiqing Liu, Lingyan Zhou, Yunhai Fu, Jinhua Zhao, Yinqi Li, Yeteng Zheng, Xiaodong Yang, Xiangjie Di, Zhiyao He

TL;DR

This study presents a promising new gene therapy approach for Duchenne Muscular Dystrophy (DMD) using lentiviral vectors (LVs) to deliver optimized mini-dystrophin genes. The LVs successfully restored dystrophin expression and improved muscle function in mouse models, demonstrating feasibility and a favorable safety profile with no observed integration into oncogenes.

What Problem Does This Paper Address?

Duchenne Muscular Dystrophy (DMD) is a severe, X-linked genetic disorder caused by mutations in the dystrophin gene, leading to progressive muscle degeneration and weakness. Current treatments, including corticosteroids and small molecules, manage symptoms but do not offer a cure. Gene replacement therapy holds great promise for a radical cure, but existing viral vectors, particularly Adeno-Associated Viruses (AAVs), face limitations such as low packaging capacity and immunogenicity, hindering their clinical application. This paper addresses the need for more effective and safer gene delivery systems for DMD, exploring lentiviral vectors (LVs) as a potential alternative due to their larger packaging capacity and lower immunogenicity.

Methods

The researchers designed and constructed four distinct lentiviral vectors, each carrying a sequence-optimized, truncated version of the human dystrophin gene. These mini-dystrophin genes were driven by a muscle-specific promoter (Spc-5-12) to ensure targeted expression.

Key methodological steps included:

  • In vitro validation: The constructed LVs were first tested in C2C12 muscle cells to confirm their ability to express mini-dystrophin. This involved assessing protein expression via Western blot and transduction efficiency using flow cytometry.
  • In vivo studies: Neonatal C57BL/10ScSn-Dmdmdx mice, a standard model for DMD, were used for in vivo experiments. The LVs were delivered via local injection into the tibialis anterior (TA) muscles.
  • Assessment of therapeutic effects: The researchers evaluated the efficacy of the LV treatment by measuring:
  • Dystrophin expression and distribution: Using immunofluorescence staining to visualize the presence and location of the restored dystrophin protein in muscle tissue over time (4, 13, and 26 weeks).
  • Muscle pathology: Hematoxylin and eosin (H&E) staining was used to assess histological changes, specifically central nucleation and mononuclear cell infiltration, which are hallmarks of DMD.
  • Muscle function: Grip strength tests were performed to quantify improvements in muscle force.
  • Genetic safety evaluation: To assess the safety of LV integration, the genomes of treated mice were sequenced using Oxford Nanopore Technologies to identify insertion sites. These sites were then compared against known oncogenes.

Datasets

Not discussed in the paper. The study primarily relies on in vitro cell cultures and in vivo animal models.

Key Insights and Ideas

  • LVs as a viable alternative to AAVs for DMD gene therapy: The study successfully demonstrates that LVs can effectively deliver functional mini-dystrophin genes into muscle tissue, overcoming some of the limitations of AAV vectors.
  • Optimized mini-dystrophin constructs show promise: The design of four different mini-dystrophin sequences, incorporating specific structural domains, allowed for a comparative analysis of their therapeutic potential.
  • Long-term expression and functional restoration: The LVs demonstrated sustained expression of mini-dystrophin for up to 6 months in vivo, leading to significant improvements in muscle strength and a reduction in pathological markers.
  • Favorable safety profile: Crucially, the study found no evidence of LV integration into oncogenes, suggesting a low risk of insertional mutagenesis and potential for cancer development.
  • Potential for reduced dosing frequency: The sustained expression observed suggests that LV-based gene therapy could potentially require less frequent administration compared to some other therapeutic approaches.

Key Results

  • In vitro: Lentiviral vectors successfully transduced C2C12 muscle cells, leading to detectable expression of mini-dystrophin, with transduction efficiencies reaching up to 83.99%.
  • In vivo dystrophin expression: Immunofluorescence showed restored dystrophin expression on the cell membrane in LV-treated mdx mice, comparable to wild-type mice, and this expression was maintained for up to 26 weeks.
  • Pathological improvements: LV treatment significantly reduced central nucleation and mononuclear cell infiltration in muscle tissue.
  • Functional recovery: Treated mice showed a significant increase in muscle pull force compared to untreated mdx mice, although it remained lower than wild-type levels.
  • Duration of effect: The therapeutic benefits, including restored dystrophin expression and improved muscle function, lasted for 3-6 months in vivo.
  • Genetic safety: Analysis of insertion sites revealed no integration into known oncogenes, indicating a good safety profile.

Limitations and Future Work

  • Limited duration of effect: While the expression lasted for up to 6 months, the researchers note that the expression of mini-dystrophin gradually decreased. They attribute this to potential immune responses against the human-derived transgene or the LV itself, and possibly less efficient transduction or maintenance of satellite cells.
  • Need for higher titers and purity: To improve outcomes, future work should focus on increasing vector titers and purity.
  • Investigating immune response: Further research is needed to understand and mitigate the immune response triggered by the LVs or the transgene.
  • Satellite cell transduction: The efficiency and duration of transduced satellite cells in vivo warrant further investigation.
  • Promoter optimization: The study suggests that the Spc-5-12 promoter might contribute to the limited duration of effect, indicating a need for promoter optimization.

Despite these limitations, the study provides a strong foundation for developing LV-based gene therapies for DMD, offering a promising avenue for future clinical translation.

Summary updated

Abstract

Duchenne muscular dystrophy (DMD) is an incurable X-linked recessive genetic disease caused by mutations in the dystrophin gene. Many researchers aim to restore truncated dystrophin via viral vectors. However, the low packaging capacity and immunogenicity of vectors have hampered their clinical application. Herein, we constructed four lentiviral vectors with truncated and sequence-optimized dystrophin genes driven by muscle-specific promoters. The four lentiviral vectors stably expressed mini-dystrophin in C2C12 muscle cells in vitro. To estimate the treatment effect in vivo, we transferred the lentiviral vectors into neonatal C57BL/10ScSn-<i>Dmd<sup>mdx</sup></i> mice through local injection. The levels of modified dystrophin expression increased, and their distribution was also restored in treated mice. At the same time, they exhibited the restoration of pull force and a decrease in the number of mononuclear cells. The remissions lasted 3-6 months in vivo. Moreover, no integration sites of vectors were distributed into the oncogenes. In summary, this study preliminarily demonstrated the feasibility and safety of lentiviral vectors with mini-dystrophin for DMD gene therapy and provided a new strategy to restore truncated dystrophin.
BibTeX
@inproceedings{wang2024duchenne,
  author = {Xiaoyu Wang and Yanghui Zhu and Taiqing Liu and Lingyan Zhou and Yunhai Fu and Jinhua Zhao and Yinqi Li and Yeteng Zheng and Xiaodong Yang and Xiangjie Di and Yang Yang and Zhiyao He},
  title = {{Duchenne muscular dystrophy treatment with lentiviral vector containing mini‐dystrophin gene in vivo}},
  booktitle = {MedComm},
  year = {2024},
  doi = {10.1002/mco2.423},
}
Figure